Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline < b > < i > BRCA1 < /i > < /b > Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

In conclusion, patients with metastatic PDAC andBRCA mutation may benefit from PARPi even after progression on chemotherapy. We hypothesize that olaparib works even in the setting of disease progression and not solely as a maintenance therapy following platinum-based therapy. Randomized trials are needed investigating the role of olaparib following disease progression in PDAC.Case Rep Oncol 2020;13:904 –910
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research